This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	IL-10	<p>Mouse studies suggest IL-10 could help treat cancer. In a mouse model of breast cancer, pegylated IL-10 increased both interferon-γ (IFNγ; IFN-γ) expression in tumor cells and CD8⁺ T cell infiltration of tumors and decreased tumor growth compared with vehicle control. Next steps could include clinical testing of pegylated IL-10. The corresponding author is CEO of Targenics Inc., a biotech developing a pegylated biologic in-licensed from Merck & Co. Inc. Additional details were not disclosed.</p> <p>SciBX 5(2); doi:10.1038/scibx.2012.37 Published online Jan. 12, 2012</p>	Patent and licensing status undisclosed	<p>Mumm, J.B. <i>et al. Cancer Cell</i>; published online Dec. 13, 2011; doi:10.1016/j.ccr.2011.11.003 Contact: Martin Oft, Merck Research Labs, Palo Alto, Calif. e-mail: martinoft@gmail.com</p>